ELT Sight Acquires Assets and IP of MLase AG Excimer Ophthalmic Laser System for Glaucoma Surgery

Martell Diagnostic Laboratories Announces HERTEST: Groundbreaking Way to Detect Effectiveness of Breast Cancer RX Globally

HERTEST is a blood test that looks for a protein called human epidermal growth factor receptor (HER2), which is shed into the blood stream of patients with growing breast cancer tumors.

ESPRIT CAM Improves Productivity for Long Part Machining by Automating Multi-spindle Program Creation

ESPRIT CAM: New computer-aided-manufacturing (CAM) technology has been introduced by ESPRIT CAM, part of Hexagon’s Manufacturing Intelligence division that provides manufacturers with the control and flexibility needed to use multi-spindle and multi-channel computer-numerical-control (CNC) machinery for the machining of long parts.

November 13, 2019: ELT Sight, Inc. today announced the company has acquired the IP and assets of MLase AG’s excimer ophthalmic laser system for glaucoma surgery. MLase manufactures and markets innovative laser systems, including the ExTra ELT Laser and disposable applicator used to perform implant-free micro-invasive glaucoma surgery. The system received European Conformity (CE) certification in 2014 and is currently available in Europe. ELT Sight plans to expand marketing activities in Europe and initiate clinical studies in the United States in early 2020. The terms for the acquisition were not disclosed.

Glaucoma is the third leading cause of blindness worldwide, and the number of affected individuals is growing as the population ages. Current treatment options, including daily eye drops and invasive shunts and stents, are suboptimal for patients and providers. Excimer Laser Trabeculostomy (ELT) is a completely implant-free micro-invasive glaucoma surgery that was first used clinically in Europe in 1997. This outpatient procedure has shown superior results and a favorable safety profile in European studies with sustained, multi-year reduced intraocular pressure (IOP) and decreased medication use.

“There is a growing need for new solutions to address glaucoma, a global health challenge expected to affect 80 million people worldwide in 2020. Clinical studies in Europe have demonstrated that the ExTra ELT Laser system offers patients with glaucoma an implant-free choice to lower eye pressure,” said Elliott Friedman, Chief Executive Officer of ELT Sight. “Our hope is to simultaneously ramp up marketing activities in Europe while conducting clinical trials in the United States early next year.”

The ExTra ELT Laser and disposable applicator will continue to be manufactured by MLase in Germany. ELT treats the pathology leading to open-angle glaucoma exactly where it occurs by increasing the permeability of the trabecular meshwork, with studies showing lower risks than other treatment methods. The outpatient procedure is completed in less than 10 minutes.

“MLase has an excellent reputation for developing and manufacturing innovative laser systems, and we look forward to collaborating with them as we focus on making this system available to the millions of patients affected by glaucoma worldwide,” Mr. Friedman added.



Related Articles